Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase 1
Completed
- Conditions
- Leukemia, Myeloid
- Registration Number
- NCT00129168
- Lead Sponsor
- Kanisa Pharmaceuticals
- Brief Summary
Chemotherapy drugs use different ways to stop cancer cells from dividing so they stop growing or die. Zosuquidar may help daunorubicin and cytarabine kill more cancer cells by making cancer cells more sensitive to the drugs. It is not yet known whether daunorubicin and cytarabine are more effective with or without zosuquidar in treating acute myeloid leukemia.
- Detailed Description
Purpose:
Phase I:
To Evaluate the safety of different doses of zosuquidar.
Phase II:
This study is designed to study the safety and effectiveness of zosuquidar when given with daunorubicin and cytarabine in newly diagnosed AML patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Newly diagnosed acute myeloid leukemia
- Ages 55-75 years
Exclusion Criteria
- Acute promyelocytic leukemia (FAB M3)
- Patients must not have received prior chemotherapy for AML.
- Prior exposure to anthracycline
- Use of any investigational agent within 4 weeks prior to enrollment into the study
For Phase II:
- Patients must be P-glycoprotein positive
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method